medigraphic.com
ISSN 0301-696X (Print)
Órgano de difusión del Servicio de Sanidad Militar y del Colegio Nacional de Médicos Militares

2019, Number 2

<< Back Next >>

Rev Sanid Milit Mex 2019; 73 (2)

Importance of PET-CT in the diagnosis of recurrence of differentiated papillary thyroid cancer

Fonseca MJV, Soto OLE, Ruiz RC, Rodríguez VCE, Mera MED

Language: Spanish
References: 37
Page: 105-119
PDF size: 291.31 Kb.


ABSTRACT

Introduction: PET-CT provides information for staging, surveillance of recurrence, and monitoring of treatment response in solid tumors. However, PET-CT is not routinely used in preoperative statification or postoperative follow-up of patients with differentiated papillary thyroid cancer (DPTC). Objective: To describe the usefulness of the use of PET-CT in the diagnosis of CDT recurrence. Material and methods: All patients under CDT surveillance who presented negative imaging studies and had elevated serum thyroglobulin levels, or who had normal thyroglobulin levels and elevated Ac anti-Tg levels were selected. These patients underwent a PET-CT and were subsequently taken to surgery or biopsy to establish the clinical-pathological finding and its correlation with the PET-CT findings. Results: Locoregional neck recurrence was documented in 33 of 56 cases (58.9%). The average SUV-MAX value was 5.86 ± standard deviation 3.53. The histopathological diagnostic variable showed a statistically significant relationship with the SUV-MAX value with a t of -2.116 and a p of 0.04. A relationship of the variables with the PET-CT findings was estimated using the SUV-MAX value using the ANOVA statistical test. The age group variable showed a statistically significant relationship with SUV-MAX with an F value of 4.47 and a p of 0.03. Conclusions: PET-CT provides an important cabinet study in the diagnosis of CDT recurrence in patients with disease not measurable by other diagnostic means and with elevated serum thyroglobulin levels, or who had normal thyroglobulin levels and elevated Ac anti-Tg levels.


REFERENCES

  1. Haugen BR, Alexander EK, Bible KC. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26 (1): 1-133.

  2. Román-González A, Restrepo L. Nódulo tiroideo, enfoque y manejo. Revisión de la Literatura. Iatreia. 2013; 26 (2): 197-206.

  3. González M, Andrades P. Sobrevida en cáncer de tiroides: seguimiento de 365 pacientes por un periodo de 37 años. Rev Chilena de Cirugía. 2002; 64 (4): 329-335.

  4. Iribarren O, Velasco N. Evolución y factores pronóstico en cáncer diferenciado de tiroides. Rev Chilena de Cirugía. 61 (2): 136-141.

  5. Martell L, Capristán M. Efectividad de la biopsia por aspiración con aguja fina con guía ecográfica en el diagnóstico de cáncer de tiroides. Rev Oncol Ecu. 2012; 22: 87-106.

  6. Peraza N, López A. Tratamiento del cáncer de tiroides en el Hospital Central Militar periodo 2005-2010. Rev Sanid Milit Mex. 2012; 66 (6): 233-241.

  7. Iribarren O, Madariaga J. Factores pronóstico de las variantes de cáncer papilar de tiroides. Rev. Chilena de Cirugía. 2010; 62 (3): 228-233.

  8. González D, Rodríguez A. Caracterización clínico-quirúrgica y anatomopatológica de la enfermedad nodular tiroidea. MEDISAN. 2012; 16 (11): 1737.

  9. Yiyan Liu. The role of 18F-FDG PET CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and or elevated antithyroglobulin antibody. Nuclear Medicine Communications. 2016; 37: 577-582.

  10. Chiovato L, Latrofa F, Braverman LE. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003; 2: 139: 346-351.

  11. Vargas H. Enfoque del paciente con nódulo tiroideo. MED. UIS. 2008; 21 (2): 76-85.

  12. Verburg FA, Luster M, Cupini C. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid. 2013; 23 (10): 1211-1225.

  13. Spencer CA. Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab. 2011; 96 (12): 3615-3627.

  14. Seo JH, Lee SW, Ahn BC, Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18) F-FDG PET/CT. Clin Endocrinol (Oxf). 2010; 72: 558-563.

  15. Saif MW, Tzannou I, Makrilia N, Syrigos K. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med. 2010; 83: 53-65.

  16. Lee JW, Lee SM, Lee DH, Kim YJ. Clinical utility of F18-FDG PET/CT concurrent with I131 therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J Nucl Med. 2013; 54: 1230-1236.

  17. Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. PET/CT in the management of thyroid cancers. Am J Roentgenol. 2014; 202: 1316-1329.

  18. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf). 2002; 57: 215-221.

  19. Viedma SS, Dorado IB, Rodríguez JR, González EN, Albertina RV, López RF et al. Use of F18 FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative T131 scan. Rev Esp Med Nucl. 2011; 30: 77-82.

  20. Kingpetch K, Pipatrattana R, Tepmongkol S, Sirisalipoch S, Chaiwatanarat T. Utility of 18-F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody. J Med Assoc Thai. 2011; 94: 1238-1244.

  21. Bogsrud TV, Hay ID, Karantanis D, Nathan MA, Mullan BP, Wiseman GA et al. Prognostic value of F18-FDG-PET in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies. Nucl Med Commun. 2011; 32: 245-251.

  22. Asa S, Aksoy SY, Vatankulu B, Aliyev A, Uslu L, Ozhan M et al. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level. Ann Nucl Med. 2014; 28:970-979.

  23. Moreno Ortega E, Vallejo Casas JA, Mena Bares LM, del Real Núñez R, Maza Muret FR, Hidalgo Ramos FJ, Latre Romero JM. Response of thyroglobulin, anti-thyroglobulin antibodies, TSH, FT4 and total T3 after rhTSH stimulation in differentiated thyroid carcinoma. Rev Esp Med Nucl. 2008; 27: 253-258.

  24. Davidson HC, Park BJ. Papilary thyroid cáncer: controversies in the manegement of neck metástasis. Laryngoscope. 2008; 118 (12): 2161-2165.

  25. Song HJ, Xue YL, Qiu ZL. Uncommon metastases from differentiated thyroid carcinoma. Hell J Nucl Med. 2012; 15 (3): 233-240.

  26. Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2011; 33 (7): 1052-1059.

  27. Yamashina M. Follicular neoplasms of the thyroid. Total circumferential evaluation of the fibrous capsule. Am J Surg Pathol. 1992; 16: 392-400.

  28. Siegel RL, Miller KD. Cancer statistics, 2016. Ca Cancer J Clin. 2016; 66: 7-30.

  29. McCormack V. GLOBOCAN 2012 (IARC). OMS.

  30. Leboulleux S, El Bez I, Borget I. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid. 2012; 8 (22): 832-838.

  31. Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013; 23 (7): 885-891.

  32. Haddad RI, Lydiatt WM. National Comprehensive Cancer Network Guidelines for Thyroid Carcinoma 2015. (NCCN).

  33. Granados M, León AM, Guerrero FJ. Cáncer diferenciado de tiroides: una antigua enfermedad con nuevos conocimientos. Gaceta Medica de México. 2014; 150: 65-77.

  34. Ozkan E, Soydal C, Araz M, Aras G, Ibis E. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels. Clin Nucl Med. 2012; 37: 755-758.

  35. Ozkan E, Aras G, Kucuk NO. Correlation of F18-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative I-131 whole-body scan results. Clin Nucl Med. 2013; 38: 326-331.

  36. Stangiersky A, Wolinsky K. The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18 F-FDG PET-CT examination. PLoS One. 2014; 9 (10): e109612.

  37. Heon Kim T, Myeon C, Young Y. SUVmax of 18 F-FGD PET/CT in the differential diagnosis of benign a malignant thyroid nodule according to tumor volume. World Journal of Surgical Oncology. 2015; 13: 217.




2020     |     www.medigraphic.com